Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina.

ABSTRACT: Nifurtimox is indicated in Chagas disease but determining its effectiveness in chronic disease is hindered by the length of time needed to demonstrate negative serological conversion. We manually reviewed long-term follow-up data from hospital records of patients with chronic Chagas disease (N = 1,497) in Argentina diagnosed during 1967-1980. All patients were aged ≥18 years at diagnosis and were either treated with nifurtimox (n = 968) or received no antitrypanosomal treatment (n = 529). The primary endpoint was negative seroconversion (the "event"), defined as a change from positive to negative in the serological or parasitological laboratory test used at diagnosis. Time to event was from baseline visit to date of endpoint event or censoring. The effectiveness of nifurtimox versus no tre

SUBMITTER: Vizcaya D 

PROVIDER: S-EPMC8489720 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature